Sunovion Pharmaceuticals Europe

Sunovion Pharmaceuticals Europe is a pharmaceutical company headquartered in London, specializing in therapies for the central nervous system (CNS) and respiratory conditions. As a subsidiary of the Japanese firm Sumitomo Pharma, it serves as the European hub for the commercialization and clinical development of the group's innovative pipeline. The company's portfolio includes treatments for schizophrenia, bipolar depression, and sleep disorders, notably the atypical antipsychotic Latuda and the wake-promoting agent Sunosi. Sunovion Europe actively collaborates with healthcare systems across the continent to improve patient outcomes in areas with significant unmet medical needs. Its research efforts are currently focused on novel mechanisms of action, such as TAAR1 agonism for psychiatric disorders.